Xyall
PrivateLast Round
Series C
Feb 11, 2026
Total Funding Raised
$20.87M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Xyall operates in Healthcare & Life Sciences and is based in Eindhoven. Its latest recorded funding round was a Series C round in February 2026.
Xyall is a medtech company that develops and provides automated tissue dissection solutions for molecular pathology testing.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotech Equipment, Precision Medicine
Business Model
B2B
Customer Profile
Hardware Sales, Hardware + Subscription, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Xyall Comparables
Compare Xyall with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Roche Holding | 75% | |
| Zeiss | 71% | |
| Morphle Labs | 71% |
For institutional investors. Book with your work email.
Xyall Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Feb 11, 2026 | ||||
| Series B | May 24, 2022 | ||||
| Series A | Jan 13, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Xyall Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Brabantse Ontwikkelings Maatschappij | Series B |
| Capricorn Partners | Series C |
| BOM Brabant Ventures | Series C, Series A |
| Health Investment Partners | Series C, Series B |
| Netherlands Enterprise Agency | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 1, 2026
Open roles increased to 12, 48% of headcount.
- Aug 1, 2026
Grew 19% QoQ, from 21 to 25 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 17, 2026
Xyall BV teams up with Tissuepathology and Indica Labs to develop an end-to-end solution for automating macro-dissection, integrating HALO AP(R) with the Xyall Tissector platform for improved throughput, consistency, and functionality at a webinar on Oct 1st '26.
For institutional investors. Book with your work email.
Xyall Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Xyall's valuation, stock price, and market status.
Is Xyall a public or private company?
Xyall is a private company.
What is the current stock price of Xyall?
Xyall is a private company, so its shares have no public market price. Caplight tracks Xyall's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Xyall worth (valuation)?
Valuation information for Xyall is not publicly available.
Can I buy Xyall stock?
Xyall shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Xyall's last funding round?
Xyall's most recent funding round was Series C on February 11, 2026.
Who are the main investors in Xyall?
Key investors in Xyall include Capricorn Partners, Health Investment Partners.
Will Xyall IPO soon?
No public IPO plans have been announced for Xyall.
How can I track Xyall secondary market activity?
Caplight tracks bids, offers, and trades in Xyall's shares on secondary markets.